Business Standard
Thursday, May 31, 2012
Sponsored by  
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
|||||Opinion|||| 
 Section Home | Editorials | Compass | BS People | Columnists | Lunch with BS
Home > Opinion & Analysis Live Markets | Commodities
 

Protectionism by another name
The EU's continued seizure of drugs in transit is untenable
Business Standard / New Delhi Nov 18, 2009, 00:15 IST

The India-European Union Joint Customs Cooperation Committee has met in New Delhi and failed to resolve the issue over Indian generic drugs being seized when they are in transit through European ports. This may be ascribed to technical reasons, but it has ramifications for international trade and, equally importantly, for public health. The stand-off comes barely weeks after the assurance by EU’s trade commissioner, Catherine Ashton, that the EU was committed to finding a solution that works for India. The EU’s plea that such seizures are made on suspicion of either violation of intellectual property rights (IPRs), notably patent laws, or of the consignments being of counterfeit drugs, holds no water because there is no evidence to back such a position. All the consignments detained so far have eventually been found to be of genuine, off-patent generic drugs on their way to countries where these are not patented.

The problem gets worse because the frequency of seizures has increased of late. This leaves only a couple of options for India. A change of route for ships carrying drugs, so that they avoid European ports, is one obvious course of action. But that would increase transportation costs, cause delays, and ultimately push up the costs and, therefore, prices of these drugs. In any case, if Indian firms prefer to export their goods through the Mediterranean, via the Suez Canal, it is because this is the shortest way to Latin American and West African destinations where people need access to cheaper drugs.

The second option for India is to take the issue to the disputes redressal body of the World Trade Organisation (WTO), as this is a clear case of the EU creating trade barriers against Indian drugs in order to boost the interests of its own firms. The issue has already been brought to the notice of the WTO’s IPR Council. Brazil, which, as an importer of generics, has been at the receiving end of such seizures, has also decried this practice, in a statement made at the last meeting of the WTO general council. As pointed out by Brazil, such seizures on baseless grounds contravene the freedom of transit norms stipulated under Article V of the General Agreement on Tariffs and Trade. This section clearly states that traffic coming from or going to the territory of other contracting parties shall not be subject to any unnecessary delays or restrictions. If the issue is not resolved, the only course for India would be to formally place it before the WTO, preferably jointly with Brazil, which appears to be a willing signatory.

Meanwhile, several other developing countries have endorsed the Indo-Brazilian stand. The controversy has given a new urgency to the debate on how to ensure affordable medicines for the poor, as also to the question of whether IPR issues can or should supersede public health concerns. The EU should be aware that, in persisting with an untenable course of action, it is risking a larger battle on a more fundamental question.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Markets end lower ahead of May F&O expiry
- Parsvnath posts Rs 23 cr loss in Q4
- Educomp net down 57% at Rs 61 cr in Jan-Mar qtr
- DLF Q4 net plunges 39% to Rs 211 cr
- Provogue Q4 net profit down 71% at Rs 1.81 cr
  Read Business news in 
- India's no. 1 Property Site. Click here to know more
- Help a Child Achieve her. Click to know more
- The Best Seller is Also the No. 1 in Mileage. Click here
- Watch The Film Here. Click here to know more..
- Learn How One City is Running on FOOD SCRAPS.
- A Brand New Server at a Price That Fits Your Budget. Click here
- 1 billion in saving for Unilever without any tangles.
- One Partnership Endless Possibilities. Click here to know more
- Helping doctors detect diseases earlier, saving costs & extending lives.
- Which is the best plan for your daughter
- Check out the TRUE COLOURS of your Stocks, Now for FREE!
- One of the leading business schools in the world.Know More
- Invest in Real Estate. Villas in Bangalore starting @ Rs.66 lacs
- 2 Lac Apartments, 1 Lac House / Plots. Click here
Sorry, comments to this story are closed
Latest Messages
Table for Two
  Now available at Special price
  Rs.280/- Only

  Buy Now
BS POLL
UPA 2 has completed three years. How do you rate its performance?  Read the story
  Good
  Average
  Bad
Submit
Most Popular
Read
E-Mailed
Commented
   
- Vodafone notice on arbitration premature: Govt
- Coal blocks for infrastructure projects get GoM nod
- Dissidence brewing in state: Senior BJP leaders team up against Modi
- Tata Motors skids as margins dip at JLR
- Rupee-sensitive stocks risky for new investors
 
 More  
Tax Shastra
  Now available at Special price
  Rs. 360/- Only

  Buy Now
  Hot Searches  
 
Apalya |  Air India |  GAAR |  Agni  |  Solar eclipse |  Satyamev Jayate |  SRK |  Aamir Khan |  IPL |  Ertiga |  Sarfaesi Act |  Vodafone |  JP Morgan |  Transfer pricing |  Rupee |  Kingfisher Airlines |  Silver |  Provident Fund |  income tax refund |  iPhone |  Reliance Industries |  SEBI |  BSNL |  BSE |  NSE |  Mukesh Ambani |  Anil Ambani |  Infosys |  Pranab Mukherjee |  Sonia Gandhi |  Rahul Gandhi |  New Pension Scheme |  Reliance |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  B-School |  Sensex |  Tax calculator |  Home Loan |  Personal Finance |  inflation |  oil prices |  Barack Obama |   
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World | General News
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us